Drug and Therapeutics Bulletin 1996;34:65-68; doi:10.1136/dtb.1996.34965
Copyright © 1996 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Three new antidepressants

Relevant BNF section: 4.3

Antidepressant drug therapy can help many people with moderate or severe depressive illness. Over 30 drugs are included in the British National Formulary for the treatment of depression, available as 40-50 branded and generic preparations. Previously we concluded that the drugs were all of similar efficacy and the differences lay in their unwanted effects and costs.1 In this article, we discuss three new antidepressants which were marketed last year - {blacktriangledown}citalopram, {blacktriangledown}nefazodone and {blacktriangledown}venlafaxine - and assess whether they hold any advantages.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1996 BMJ Publishing Group Ltd.